The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-04. Anything still debated is marked as such rather than presented as settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
=== Animal health === Livestock products ($3.4 billion in 2024 revenues) include various medications and vaccines for cattle and poultry. Companion animal products ($2.4 billion in 2024 revenues) include various medications and vaccines for cats, dogs, and horses.
Friendly AI are machines that have been designed from the beginning to minimise risks and to make choices that benefit humans. Eliezer Yudkowsky, who coined the term, argues that developing friendly AI should be a higher research priority: it may require a large investment and it must be completed before AI becomes an existential risk. Machines with intelligence have the potential to use their intelligence to make ethical decisions. The field of machine ethics provides machines with ethical principles and procedures for resolving ethical dilemmas. The field of machine ethics is also called computational morality, and was founded at an AAAI symposium in 2005. Geoffrey Hinton has suggested researchers explore instilling human-aligned values, such as compassion, into AI systems as a safeguard, speculating about the possibility of building "maternal instincts" into AI models, so “they really care about people”. Other approaches include Wendell Wallach's "artificial moral agents" and Stuart J. Russell's three principles for developing provably beneficial machines.
Shortly before World War II, Czechoslovakia ceased to exist. Its territory was divided into the Protectorate of Bohemia and Moravia, the newly declared Slovak State and the short-lived Republic of Carpathian Ukraine. While much of former Czechoslovakia came under the control of Nazi Germany, Hungarian forces swiftly overran the Carpathian Ukraine. Hungary annexed some areas (e.g., Southern Slovakia and Carpathian Ruthenia) in the autumn of 1938. Poland reclaimed Zaolzie previously annexed by the Czechs during the Polish-Soviet war in 1920. The Zaolzie region became part of Nazi Germany after the German invasion of Poland in September 1939. The German economy—burdened by heavy militarisation—urgently needed foreign currency. Setting up an artificially high exchange rate between the Czechoslovak koruna and the Reichsmark brought consumer goods to Germans (and soon created shortages in the Czech lands). Czechoslovakia had fielded a modern army of 35 divisions and was a major manufacturer of machine guns, tanks, and artillery, most of them assembled in the Škoda factory in Plzeň. Many Czech factories continued to produce Czech designs until converted to German designs. Czechoslovakia also had other major manufacturing companies. Entire steel and chemical factories were moved from Czechoslovakia and reassembled in Linz (which incidentally remains a heavily industrialized area of Austria).
== Treatment == The primary treatment of PPID is pergolide, a dopamine agonist that provides suppression to the pars intermedia in place of the dysfunctional hypothalamus. Horses should be reassessed in 30 days following the start of treatment, through evaluation of clinical signs and by baseline diagnostic testing, to ensure the appropriate dose is being prescribed. Results from that test dictate changes in dose. Horses that are responding to treatment should be retested every 6 months, including a test in the autumn when a seasonal increase in ACTH occurs, to ensure their ACTH levels are appropriately suppressed during this time. Drug side effects include a transient decrease in appetite, typically seen when first introducing the medication or increasing the dose, which can be reduced by slowly increasing the dose to therapeutic levels, and by breaking up the daily dose into twice-daily administrations. Attitude, activity levels, hyperglycemia, and increased drinking and urination are usually improved within 30 days of initiating treatment. Other clinical signs, such as hirsutism, potbellied appearance, muscle wasting, laminitic episodes, and increased predisposition to infection, usually take between 30 days and a year to improve. Cyproheptadine may be added to the treatment regimen in horses that are inadequately responding to pergolide, but is usually only used in horses with advanced PPID on high doses of pergolide.
While some EU member states have privatised all, and some part, of their telecomms infrastructure, publicly or community-owned internet providers (such as in Denmark or Romania) tend to have the fastest web speeds.
Sources: en.wikipedia.org
Balance of terror Balance of threat Mutual assured destruction – a theory in which two or more states are balanced by their ability to effectively completely destroy each other Negarchy Offshore balancing Peace through strength Polarity (international relations) Soft balancing Sphere of influence Superpower Strategic autonomy In history:
==== Stapled trans-anal rectal resection ==== Stapled trans-anal rectal resection (STARR) is a minimally invasive procedure which involves removal of a circumferential portion of mucosa with a circular surgical stapler via the anal canal. The anterior wall of the anorectal junction is reinforced. A variant of the procedure is the Contour Transtar, which may have slightly better results for IRP and obstructed defecation. Research shows that symptoms improve after STARR in patients with obstructed defecation and IRP or rectocele. However, there is a high rate of complications (including sometimes serious complications), and a high rate of recurrence of the procedure. If there is fecal incontinence, transanal approach is contraindicated. This is because incontinence and bowel urgency frequently get worse after STARR, although this may not be permanent. Coexistence of IRP and enterocele is a relative contraindication for the STARR procedure. The use of STARR has become less common, and some surgeons have abandoned this procedure.
=== Homo-FRET === In general, "FRET" refers to situations where the donor and acceptor proteins (or "fluorophores") are of two different types. In many biological situations, however, researchers might need to examine the interactions between two, or more, proteins of the same type—or indeed the same protein with itself, for example if the protein folds or forms part of a polymer chain of proteins or for other questions of quantification in biological cells or in vitro experiments. Obviously, differences in conventional UV-vis spectra will not be the tool used to detect and measure homogeneous FRET, as both the acceptor and donor emit light with the same wavelengths. However, there is evidence that certain nonlinear spectroscopies may provide signatures of homogeneous FRET that would be invisible in linear spectra. Yet researchers can detect differences in the polarisation between the light which excites the fluorophores and the light which is emitted, in a technique called FRET anisotropy imaging; the level of quantified anisotropy (difference in polarisation between the excitation and emission beams) then becomes an indicative guide to how many FRET events have happened. In the field of nano-photonics, FRET can be detrimental if it funnels excitonic energy to defect sites, but it is also essential to charge collection in organic and quantum-dot-sensitized solar cells, and various FRET-enabled strategies have been proposed for different opto-electronic devices. It is then essential to understand how isolated nano-emitters behave when they are stacked in a dense layer.
Sedimentation equilibrium experiments reports the molar mass of analytes and their chemical equilibrium constants. The rotor speed is adjusted such that a steady-state concentration profile c(r) of the sample in the cell is formed, where sedimentation and diffusion cancel out each other. Ultracentrifuge Gas centrifuge Theodor Svedberg Differential centrifugation Buoyant density ultracentrifugation Zippe-type centrifuge Reversible Associations in Structural and Molecular Biology (RASMB -an Analytical Ultracentrifugation Forum) Analytical Ultracentrifugation as a Contemporary Biomolecular Research Tool. Archived 2002-08-04 at the Wayback Machine Gilbert-Jenkins theory Archived 2007-05-01 at the Wayback Machine Report on an ultracentrifuge explosion.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Reverse-phase liquid chromatography and mass spectrometry are the most common techniques. Chromatography assesses purity, while mass spectrometry confirms molecular identity. Additional methods may be applied when higher confidence is required.